tirzepatide cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized CT-388 vs Tirzepatide: Signaling-Biased Dual

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5

It is being investigated for its potential in treating neurodegenerative diseases and cognitive impairment

Weight regain occurs in most patients after discontinuation, with approximately 50-70% of lost weight returning within 12 months

Stop by today and claim your FREE 12 oz Activator Recovery GLP-1 Almond Berry when you apply the reward in your Healthy Rewards app.* #free #glp1weightloss #glp1 #glp1community Stop by today and claim your FREE 12 oz Activator Recovery GLP-1 Almond Berry when you apply the reward in your Healthy Rewards app.* #free #glp1weightloss #glp1 #glp1community

7 Validates patient daytime phone number and extension formatting Ensures the Patient preferred daytime phone number includes a valid North American numbering plan format (10 digits, allowing separators) and that the extension (if provided) is numeric and within a reasonable length

This is especially useful during the active weight-loss phase, when more frequent monitoring provides the most value